ArticleCancer medicine2025
Clinical Features and Outcomes of Primary Colorectal Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPrimary gastrointestinal (GI) diffuse large B-cell lymphoma (DLBCL) is a rare malignancy. Given its rarity, the nature of the disease, particularly those originating in the colorectum, remains poorly defined.
aimsThis multicenter retrospective study analyzed the clinical characteristics and treatment outcomes of primary GI DLBCL, with a focus on colorectal cases. MATERIALS &
methodsA total of 104 cases of primary GI DLBCL were retrospectively collected from three institutions (2010-2024) and classified into three groups based on the lymphoma's origin.
resultsAmong 104 patients, 57.7% had gastric, 18.3% small bowel, and 24.0% colorectal DLBCL. Approximately 60% presented with limited-stage disease (Stage I-II). All patients received front-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), achieving a complete remission (CR) rate of 81.0%. The estimated 3-year overall survival (OS) and progression-free survival (PFS) were 91.7% and 91.9%, respectively. Outcomes varied by disease origin, with gastric DLBCL showing the most favorable prognosis and small bowel the poorest (3-year OS 93.9% vs. 69.3%). DISCUSSION: In the colorectal subgroup (n = 25), 84.0% had disease in the ascending colon, and 70.0% had limited-stage disease. Obstructive symptoms were the most common initial presentation. The CR rate after R-CHOP was 80.0%, with estimated 3-year OS and PFS of 86.7% and 72.3%, respectively. While primary tumor resection improved local disease control, it did not confer an OS benefit. During follow-up, 13.5% of patients experienced relapse, most frequently more than 12 months after achieving CR. Relapsed or refractory primary GI DLBCL demonstrated better outcomes than conventional relapsed nodal DLBCL.
conclusionThese findings confirm the efficacy of front-line R-CHOP in primary GI DLBCL and suggest that primary tumor resection may be a useful component of treatment for localized primary colorectal DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.